MacroGenics VP Jon Marc Wigginton Unloads 5,000 Shares (MGNX)
MacroGenics (NASDAQ:MGNX) VP Jon Marc Wigginton sold 5,000 shares of the stock on the open market in a transaction dated Monday, August 18th. The stock was sold at an average price of $20.52, for a total transaction of $102,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on MGNX. Analysts at Oppenheimer initiated coverage on shares of MacroGenics in a research note on Thursday, July 10th. They set an “outperform” rating and a $48.00 price target on the stock. Separately, analysts at Roth Capital raised their price target on shares of MacroGenics from $28.00 to $30.00 in a research note on Thursday, June 19th. Finally, analysts at Roth Capital initiated coverage on shares of MacroGenics in a research note on Monday, June 9th. They set a “buy” rating and a $28.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $50.50.
Shares of MacroGenics (NASDAQ:MGNX) traded down 0.57% on Tuesday, hitting $20.79. 77,866 shares of the company’s stock traded hands. MacroGenics has a 1-year low of $17.96 and a 1-year high of $41.00. The stock has a 50-day moving average of $20.29 and a 200-day moving average of $24.84. The company’s market cap is $576.7 million.
MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.15. Analysts expect that MacroGenics will post $-1.39 EPS for the current fiscal year.
MacroGenics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases.
Receive News & Ratings for MacroGenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.